New segment model on human lung cancer

We are thrilled to launch our new model of Non-Small Cell Lung Cancer. We use patient-derived xenografts as well as mouse allografts to replicate clinical features of this devastating condition. Join us today on our quest for accelerating preclinical drug discovery and combating lung cancer. Explore this and other segment models here: https://ivrs.se/segment-models/ If you have […]

IVRS appointed as industry winners 2022!

IVRS was recently appointed as industry winners or ‘’Branschvinnare’’, which is awarded to Swedish companies who have reached exceedingly positive revenue and result changes during the year. See what our CEO, Ramin Massoumi, had to say on the matter: Our mission has always been to bridge the gap between preclinical and clinical studies by offering flexible projects by […]